ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.

The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C), and cisplatin, has been shown to be active against refractory or relapsed non-Hodgkin's lymphoma (NHL) in therapeutic trials. We undertook this study to deter...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Chul Won, Paek, Chang Won, Seo, Jae Hong, Kim, Byung Soo, Shin, Sang Won, Kim, Yeul Hong, Kim, Jun Suk
Formato: Texto
Lenguaje:English
Publicado: Korean Academy of Medical Sciences 2002
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3054931/
https://www.ncbi.nlm.nih.gov/pubmed/12378012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3054931/
https://www.ncbi.nlm.nih.gov/pubmed/12378012

Ejemplares similares